Analgesic efficacy of the cyclooxygenase-2-specific inhibitor rofecoxib in post-dental surgery pain: A randomized, controlled trial

Clinical Therapeutics

Volumn 21, Issue 6, 1999, Pages 943-953

  Morrison, Briggs W ^a   Christensen, Steven ^b   Yuan, Weiying ^a   Brown, Jean ^c   Amlani, Susan ^a   Seidenberg, Beth ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Private Practice   (United States)

^c Jean Brown Associates Inc   (United States)

Author keywords

Analgesic; Cyclooxygenase 2 specific inhibitor; Ibuprofen; Postoperative dental pain; Rofecoxib

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; IBUPROFEN; PLACEBO; ROFECOXIB; UNCLASSIFIED DRUG;

ADULT; ANALGESIA; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENTAL SURGERY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; ENZYME INHIBITION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDIATOR RELEASE; ORAL DRUG ADMINISTRATION; POSTOPERATIVE PAIN; PROSTAGLANDIN SYNTHESIS; RANDOMIZED CONTROLLED TRIAL; RECEPTOR UPREGULATION; TOOTH PAIN;

EID: 0032795598     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(99)80016-2     Document Type: Article

References (24)

1. 1. Forbes JA. Oral surgery. In: Max MB, Portenoy RK, Laska EM, eds. Advances in Pain Research and Therapy: The Design of Analgesic Clinical Trials. New York: Raven Press: 1991:347-374.
2. 2. Roszkowski MT, Swift JQ, Hargreaves KM. Effect of NSAID administration on tissue levels of immunoreactive prostaglandin E2, leukotriene B4, and (s)-flurbiprofen following extraction of impacted third molars. Pain. 1997;3:339-345.
3. 3. Seibert K, Masferrer JL. Role of inducible cyclooxygenase (COX-2) in inflammation. Receptor. 1994;4:17-23.
4. 4. Smith TJ. Cyclooxygenases as the principal targets for the action of NSAIDs. Rheum Dis Clin North Am. 1998;24:501-523.
5. 5. DeWitt D. Prostaglandin endoperoxide synthase: Regulation of enzyme expression. Biochim Biophys Acta. 1991;1083:121-134.
6. 6. Yamagata K, Andreasson KI, Kaufmann WE, et al. Expression of a mitogen-inducible cyclooxygenase in brain neurons: Regulation by synaptic activity and glucocorticoids. Neuron. 1993;11:371-386.
7. 7. Kömhoff M, Gröne H-J, Klein T, et al. Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: Implication for renal function. Am J Physiol. 1997;272:F460-F468.
8. 8. Meade EA, Smith WL, DeWitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem. 1993;268:6610-6614.
9. 9. O'Neill GP, Mancini JA, Kargman S, et al. Overexpression of human prostaglandin G/H synthase-1 and -2 by recombinant vaccinia virus: Inhibition by nonsteroidal anti-inflammatory drugs and biosynthesis of 15-hydroxyeicosatetraenoic acid. Mol Pharmacol. 1994;45:245-254.
10. 10. Laneuville O, Breuer DK, DcWitt DL, et al. Differential inhibition of human prostaglandin endo-peroxide H synthases-1 and -2 by nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther. 1994;271:927-934.
11. 11. Kargman S, Wong E, Greig GM, et al. Mechanism of selective inhibition of human prostaglandin G/H synthase-1 and -2 in intact cells. Biochem Pharmacol. 1996;52:1113-1125.
12. 12. Berg J, Christoph T, Widerna M, Boden teich A. Isoenzyme specific cyclooxygenase inhibitors: A whole cell assay system using the human erythroleukemic cell line HEL and the human monocytic cell line mono mac 6. J Pharmacol Toxicol Methods. 1997:37:179-186.
13. 13. Wong E, DeLuca C, Boily C, et al. Characterization of autocrine inducible prostaglandin H synthase-2 (PGHS-2) in human osteosarcoma cells. Inflamm Res. 1997;46: 51-59.
14. 14. Miralpeix M, Camacho M, Lopez-Belmonte J, et al. Selective induction of cyclo-oxygenase-2 activity in the permanent human endothelial cell line HUV-EC-C. Biochemical and pharmacological characterization. Br J Pharmacol. 1997;121:171-180.
15. 15. Ehrich EW, Dallob A, de Lepeleire 1, et al. Characterization of rofecoxib as a cyctooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model. Clin Pharmacol Ther. 1999:65:336-347.
16. 16. Mehlisch DR, Fulmer RI. A crossover comparison of bromfenac sodium, naproxen sodium, and placebo for relief of pain from primary dysmenorrhea. J Women's Health. 1997;6:83-92.
17. 17. Cox DR, Regression models and life tables. J R Stat Soc Series B. 1972;34: 187-220.
18. 18. Hosmer DW, Lemeshov S. Applied Logistic Regression. New York: John Wiley & Sons, Inc; 1989.
19. 19. Cooper SA. Five studies on ibuprofen for postsurgical dental pain. Am J Med. 1984;77:70-77.
20. 20. Desjardins PJ, Black PM, Balm TK, et al. Onset of analgesia: Further validation of a new stopwatch method. Clin Pharmacol Ther. 1996;59:130. Abstract.
21. 21. Ehrich E, Schnitzer T, Kivitz A, et al. MK-966, a highly selective Cox-2 inhibitor, was effective in the treatment of osteoarthritis (OA) of the knee and hip in a 6-week placebo controlled study. J Rheum. In press.
22. 22. Cannon G, Caldwell J, Holt P, et al. MK-0966, a specific Cox-2 inhibitor, has clinical efficacy comparable to diclofenac in the treatment of knee and hip osteoarthritis (OA) in a 26-week controlled clinical trial. Arthritis Rheum. 1998;41(Suppl 9): S196. Abstract.
23. 23. Saag K, Fisher C, McKay J, et al. MK-0966, a specific Cox-2 inhibitor, has clinical efficacy comparable to ibuprofen in the treatment of knee and hip osteoarthritis (OA) in a 6-week controlled clinical trial. Arthritis Rheum. 1998;41(Suppl 9): S196. Abstract.
24. 24. Morrison BW, Daniels SE, Kotey P, et al. Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrhea: A randomized controlled trial. Obstet Gynecol. In press.